Overview

Alternate Day Buprenorphine Administration, Phase XI - 16

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate open buprenorphine dosing with dose choice after open exposure.
Phase:
Phase 2
Details
Lead Sponsor:
University of Vermont
Collaborator:
National Institute on Drug Abuse (NIDA)
Treatments:
Buprenorphine